What is Retatrutide?
Retatrutide is an investigational triple agonist that targets GIP, GLP-1, and glucagon receptors. It is not an FDA-approved medication, but it attracts heavy research and buyer interest because early clinical studies reported very large body-weight reductions compared with older incretin therapies.
For VialVerdict shoppers, the safest comparison point is not hype around results. Compare suppliers by product-specific COA/HPLC visibility, vial size, price per mg, cold-chain or domestic shipping clarity, refund policy, and whether the vendor has credible review signals for retatrutide listings.
How it works
- Activates GLP-1 signaling linked to appetite reduction, slower gastric emptying, and glucose-dependent insulin response.
- Adds GIP receptor activity, which is researched for insulin sensitivity, lipid metabolism, and weight-management synergy with GLP-1 pathways.
- Adds glucagon receptor activity, the main differentiator from tirzepatide, with research interest around energy expenditure and fat oxidation.
Primary effects
- Weight-management research
- Appetite and satiety signaling
- Glucose-metabolism models
- Energy-expenditure and fat-oxidation research
Common side effects
- Nausea, especially during titration
- Constipation, diarrhea, or reflux-like GI discomfort
- Fatigue or appetite suppression that may require monitoring
- Unknown long-term safety profile outside investigational settings